Loading cancer entity…
Loading cancer entity…
Variants & evidence
1,206 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MET D1010N2 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4780In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4781In a metastatic lung squamous cell carcinoma patient harboring a MET D1010N mutation, MET D1010N mutation was associated with response to crizotinib monotherapy. The patient maintained initial respons… (full text at CIViC) PMID 27022036 · Heist et al., 2016 · Open in CIViC | civic |
| MET D1010Y1 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4778In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC) PMID 27343443 · Schrock et al., 2016 · Open in CIViC | civic |
| MET D1228N1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID1652Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation. PMID 27343442 · Heist et al., 2016 · Open in CIViC | civic |
| MET D1228V2 | ||||||||
| Cabozantinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1864Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC | civic |
| Savolitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 4 | accepted | EID1865Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC | civic |
| MET Exon 14 Mutation2 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7840In a phase 2 trial, patients with NSCLC harboring MET alterations were treated with crizotinib. MET alterations were kinase domain activating mutations included V1110L, H1112L, H1112Y, H1124D, M1149T,… (full text at CIViC) PMID 31932802 · Drilon et al., 2020 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7503In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC) PMID 31416808 · Landi et al., 2019 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation33 | ||||||||
| (prognostic) | Lung Adenosquamous CarcinomaALIAS | Prognostic | C | Supports Poor Outcome | 2 | submitted | EID11411A 33-year old male patient (non-smoker) was diagnosed with Stage IVB adenosquamous lung carcinoma. Various treatment strategies were tried but all had progressive disease quickly after treatment. Next… (full text at CIViC) PMID 33854337 · Jiao et al., 2021 · Open in CIViC | civic |
| Cabozantinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11400A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| Capmatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | ||||||
| CD274 Overexpression + MET Exon 14 Skipping MutationCD274MET8 | ||||||||
| Carboplatin/Pemetrexed Regimen + PembrolizumabCombination | Lung Sarcomatoid Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11457A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC) PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC | civic |
| Nivolumab | Lung Sarcomatoid Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11414A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC) PMID 35110965 · Gu et al., 2022 · Open in CIViC | civic |
| MET D1228N + MET Exon 14 Skipping Mutation1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | submitted | EID11403An 83-year old male (smoker) was diagnosed with adenocarcinoma of right upper lung. Next-generation sequencing (NGS) analysis found MET exon 14 skipping mutation and MET C526F mutation and the patient… (full text at CIViC) PMID 31055074 · Jin et al., 2019 · Open in CIViC | civic |
Data updated 4 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| A |
| Supports Sensitivity Response |
| 4 |
| accepted |
EID8847In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, fr… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC |
| civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1186A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+. PMID 25971938 · Frampton et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7795An 82 year old with metastatic NSCLC had disease recurrence 39 months after complete surgical resection. Genomic profiling of the primary resection harbored a MET variant c.3028G>C, as well as a frame… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11417A 65-year old female (non-smoker) presented with right leg pain and edema. Percutaneous needle biopsy was performed on a mass-like lesion that appeared in a chest x-ray and revealed moderately differe… (full text at CIViC) PMID 36072511 · Kim et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Adverse Response | 2 | submitted | EID11409A 68-year old male (former smoker: 50 pack-years) was diagnosed with stage IV lung adenocarcinoma with pleural disseminations and positive intra-abdominal lymph node. Analysis of tumor tissue showed a… (full text at CIViC) PMID 33347701 · Kanemura et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12866H596 cells harboring mutant c-MET due to exon 14 deletion were shown to be sensitive to capmatinib (INCB28060) inhibiting phospho-c-MET in in vitro ELISA studies. IC50s were 0.4 nM for H596 cells. Cap… (full text at CIViC) PMID 21918175 · Liu et al., 2011 · Open in CIViC | civic |
| Carboplatin/Pemetrexed Regimen + PembrolizumabCombination | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11487An 81-year old man (smoker: 40 cigarettes/day) presented with metastatic lung adenocarcinoma. No genetic variants appeared on first round genetic testing on the Oncomine Dx Target TEst Multi-CDx syste… (full text at CIViC) PMID 37007311 · Nitta et al., 2023 · Open in CIViC | civic |
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11416780 patients with lung cancer were included in this retrospective study. 16 patients with MET mutations were identified, consisting of 7 with MET exon 14 skipping mutations. Analysis of survival of th… (full text at CIViC) PMID 35679833 · Shalata et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7640Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib. MET amplification was defined as more than or equal to 6 copies. The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 1 | accepted | EID7642Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with … (full text at CIViC) | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID797We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping. PMID 25971939 · Paik et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1185A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to… (full text at CIViC) PMID 26729443 · Awad et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11384A 68-year old woman (former smoker: 24 pack-years) was diagnosed with advanced lung adenocarcinoma. Genomic profiling yielded MET exon 14 skipping mutation (c.e14 1 G>A), PIK3CA mutation (c.1624 G>A),… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11395A 59-year old woman was diagnosed with lung adenocarcinoma after a 15 cm right upper lobe lung mass was found with multiple lymph nodes and pleural nodules. Next-generation sequencing revealed a MET e… (full text at CIViC) PMID 30553716 · Rotow et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11398A 67-year old Asian woman (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural and rib disease. The patient underwent a lobectomy and then received carboplatin/paclitaxel/bevacizumab. … (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1651Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib. PMID 26845194 · Shea et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7643In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of c… (full text at CIViC) PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID11391A 60-year old woman (non-smoker) was diagnosed with stage IV lung adenocarcinoma after finding a 5.7 x 5.1 cm left pleural-based mass with multiple invasions. The patient was put on carboplatin and pe… (full text at CIViC) PMID 27987579 · Dong et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID11399A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. She received six cycles of carboplatin/pemetrexed which was followed by pemetrexed main… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11401A 62-year old Asian man (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural metastases. He received pemetrexed, docetaxel, nivolumab, and gemcitabine. Genetic testing revealed MET exo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID4786In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12) treated with crizotinib monotherapy, was associated with a response as evident … (full text at CIViC) PMID 25769807 · Jenkins et al., 2015 · Open in CIViC | civic |
| Cabozantinib + CrizotinibSequential | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11410A 77-year old woman was diagnosed with lung adenocarcinoma harboring a MET exon 14 skipping mutation after PET-CT scans showed a right upper lobe mass, right hilar enlarged lymph nodes, and multiple b… (full text at CIViC) PMID 33530219 · Qin et al., 2021 · Open in CIViC | civic |
| Savolitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11474A 49-year old female (non-smoker) presented with a 3.8 x 2.9 cm mass that was diagnosed as Stage IIIA lung adenocarcinoma. Genetic testing revealed a MET exon 14 skipping mutation, to which the patien… (full text at CIViC) PMID 36052259 · Fu et al., 2022 · Open in CIViC | civic |
| Tepotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID8848In this open-label phase 2 trial, MET inhibitor tepotinib was administered to patients with non-small cell lung cancer and MET exon 14 skipping mutation found in either liquid and/or tissue biopsy. A … (full text at CIViC) PMID 32469185 · Paik et al., 2020 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11766In the VISION phase 2 trial (NCT02864992), 313 patients with advanced, metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations were treated with 500 mg/kg tepotinib daily. In t… (full text at CIViC) PMID 37270698 · Mazieres et al., 2023 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7272In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.… (full text at CIViC) | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID11465A 56-year old male (smoker: 50 pack-years) was diagnosed with stage IIIA lung adenocarcinoma. Patient underwent four cycles of cisplatin and pemetrexed and maintenance therapy with pemetrexed but was … (full text at CIViC) PMID 33387444 · Tanaka et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11415An 84-year old man (smoker: 62-pack-years) was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) and was started on carboplatin and nab-paclitaxel. After the tumor progressed, the patient wa… (full text at CIViC) PMID 35383870 · Tanaka et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11476A 57-year female (non-smoker) was diagnosed with lung adenocarcinoma via pleural fluid cytology. After multigene testing revealed MET exon 14 skipping mutation, the patient was switched from cisplatin… (full text at CIViC) PMID 36810936 · Ikeo et al., 2023 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11464A 75-year old woman presented with lung adenocarcinoma (stage IVA) to which next-generation sequencing revealed METex14del. The patient was put on crizotinib (500 mg/day) and showed partial response f… (full text at CIViC) PMID 33533182 · Takamori et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11477A 60-year old male (smoker: 38 pack-years presented with stage IIB lung adenocarcinoma. After receiving an upper lobectomy, the left lobar lymph node was pathologically positive and received cisplati… (full text at CIViC) PMID 37228358 · Onodera et al., 2023 · Open in CIViC | civic |
| Lung Non-Small Cell CarcinomaCURATED_BROADER |
| Predictive |
| B |
| Does Not Support Sensitivity Response |
| 2 |
| submitted |
EID11419Twenty-four patients with MET exon 14 skipping mutation and PD-L1 expression >50% were included in this retrospective study. Median overall survival of these patients was 12.1 months (CI: 9.1 - NR) an… (full text at CIViC) PMID 36210290 · Guisier et al., 2022 · Open in CIViC |
| civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 3 | submitted | EID11396A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC) PMID 30600919 · Baba et al., 2019 · Open in CIViC | civic |
| Carboplatin + PemetrexedCombination | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11397A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC) PMID 30600919 · Baba et al., 2019 · Open in CIViC | civic |
| Tepotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID11463A 77-year old woman presented with metastatic lung adenocarcinoma with MET exon 14 skipping mutation and PD-L1 tumor proportion score of 90%. Pembrolizumab was given but progressed after 1 year. Lepto… (full text at CIViC) PMID 34590003 · Ninomaru et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11460A 75-year old female (non-smoker) was diagnosed with stage IVA lung adenocarcinoma harboring PD-L1 overexpression (tumor proportion score = 90%). After preliminary treatments became resistant and were… (full text at CIViC) PMID 35252894 · Hashiguchi et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11695A 86-year old male (former smoker) presented to the hospital after an accidental fall. PET/CT confirmed lung adenocarcinoma with sarcomatoid transformation. Immunohistochemical evaluation and next-gen… (full text at CIViC) PMID 37840886 · Inno et al., 2023 · Open in CIViC | civic |